Jefferies Global Healthcare Conference
Logotype for DKSH Holding AG

DKSH (DKSH) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for DKSH Holding AG

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Industry shifts and partnership model

  • Emerging biopharma accounts for 60% of the pipeline; China contributes more than 30% of the global pipeline, including first-in-class innovation.

  • The largest pharma patent cliff in history is expected over the next 3 years; MFN pressure and geopolitics are reshaping profitability and launch sequencing.

  • Three-quarters of industry value is concentrated in the top 10 markets; outsourcing is growing as pharma scales back direct presence in long-tail markets and biotech seeks scaled commercialization partners.

  • Partner expectations are shifting from distribution to regional and global integrated platforms focused on specialty and rare disease, launch excellence, patient access, compliance, and beyond-the-pill services.

Platform ambition and capabilities

  • Ambition: become a leading global integrated healthcare platform serving patients across most of the world, with specialty and rare-disease capabilities and growth from in-licensing and own brands.

  • Healthcare net sales were CHF 5.8 billion last year, with reach across 17 Asia Pacific markets and more than 4,000 commercial associates; coverage excludes China, Japan, and India.

  • Medical affairs includes more than 70 associates; digital patient solutions serve more than 120,000 patients, with 30,000 active HCPs and nearly 300 specialty brands.

  • Coverage spans payer, prescriber, and frontier markets across Asia Pacific; therapeutic areas include oncology, hematology, immunology, neuroscience, rare disease, and others, reaching more than 75,000 physicians.

  • Launch planning starts 2.5–3 years ahead, combining medical engagement and access planning; post-approval execution focuses on message, customer, channel, and frequency.

Growth and geographic expansion

  • A Japanese specialty pharma outsourced its full portfolio in Q4 2024; a Singapore metabolic medicine launch overtook its competitor within 6 months.

  • Recent agreements include a U.S. biopharma launch portfolio in Hong Kong and Macau, pain launches in 8 APAC markets, and a rare cardiovascular medicine planned for Australia, Korea, Taiwan, and Singapore.

  • The recently announced NewBridge Pharma acquisition adds a presence in 14 Middle East and North Africa markets, with specialty and rare-disease capabilities.

  • Brand acquisitions include Myonal and Merislon in 9 markets, Bayer’s Meliane in 30 markets, and Roche Pharma’s Rocephin in 80 markets.

  • Priorities are extending the global platform, strengthening launch capabilities, and expanding in-licensed and own-brand portfolios.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from DKSH